Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

Posted: May 11, 2025 at 2:45 am

Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response

See the rest here:
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

Related Posts